NCT02214381 is a Phase 3 clinical trial of Myocet in Early Primary Breast Cancer, sponsored by West German Study Group.

Who is sponsoring NCT02214381?

NCT02214381 is sponsored by West German Study Group.

What drugs are being tested in NCT02214381?

Interventions in NCT02214381: Myocet, Cyclophosphamide, Paclitaxel.

What condition does NCT02214381 study?

NCT02214381 studies Early Primary Breast Cancer.

Is NCT02214381 still recruiting?

NCT02214381 is currently completed. Last updated 25 February 2025.

Last reviewed 2025-02-25 · How we verify

NCT02214381

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Prospective, Multicenter, Open-label Comparison of Pre-surgical Myocet/ Cyclophosphamide (MC) q3w Followed by Either MC or Paclitaxel - Depending on Early Response Assessment by Ultrasound or by Toxicity for Elderly Non Frail Primary Breast Cancer Patients With Increased Risk of Relapse.

Completed Phase 3 Last updated 25 February 2025

What this trial tests

Phase 3 trial testing Myocet in Early Primary Breast Cancer in 80 participants. Completed in 15 January 2025.

Timeline

1 July 2014

Primary endpoint
1 October 2015

15 January 2025

Quick facts

Lead sponsor	West German Study Group
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	1 July 2014
Primary completion	1 October 2015
Estimated completion	15 January 2025
Sites	2 locations across Germany

Drugs / interventions tested

Myocet — full drug profile →
Cyclophosphamide (cyclophosphamide) — full drug profile →
Paclitaxel — full drug profile →

Conditions studied

Early Primary Breast Cancer — all drugs for Early Primary Breast Cancer →

Sponsor

West German Study Group — full company profile →

Who can join

70 and older, female only, with Early Primary Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Comparison of pCR rates in patients with early response and no severe toxicity (Group 1) and in other patients (Group 2).
Time frame: After 5 years of follow-up.

Sponsor's own description

Comparison of pre-surgical Myocet/ Cyclophosphamide (MC) q3w followed by either MC or Paclitaxel - depending on early response assessment by ultrasound or by toxicity for elderly non frail primary breast cancer patients with increased risk of relapse.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Myocet

Trials testing the same drug.

NCT03643276 — Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 · Phase 3 · recruiting

Other West German Study Group trials

Trials by the same sponsor.

NCT07242352 — Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinica · Phase 3 · not yet recruiting
NCT07178730 — NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple- · Phase 3 · not yet recruiting
NCT03988036 — A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast C · Phase 2 · completed
NCT04055493 — Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC · Phase 3 · active not recruiting
NCT02269813 — PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative B · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02214381 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by West German Study Group
Last refreshed: 25 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02214381.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing